Opiant Pharmaceuticals, Inc.
OPNTDelisted Mar 2, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001385508
Opiant Pharmaceuticals, Inc. was delisted on Mar 2, 2023; its insiders filed their last Form 4 on Mar 3, 2023; 37 institutions reported holding it in 13F filings for Q4 2022, worth $43.2M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 37
- Q4 2022, +6 vs. previous quarter
- 13F value
- $43.2M
- Reported value at the end of Q4 2022
- Superinvestors holding
- 0
- At the end of Q4 2022
Superinvestors holding OPNT, Q4 2022
No superinvestor reported holding OPNT at the end of Q4 2022.
Latest insider trades
Open-market purchases and sales by Opiant Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 31, 2023 (view filing) | Jan 27 | 4 days | Crystal RogerChief Executive Officer | SSale | −1.36K | $20.26 | −$27.5K | −1.8%75.3K after | |
| Jan 31, 2023 (view filing) | Jan 27 | 4 days | Ellison Mark Jason HeathChief Development Officer | SSale | −610 | $20.26 | −$12.4K | −3.2%18.8K after | |
| Jan 31, 2023 (view filing) | Jan 27 | 4 days | Gorman BrianOther: General Counsel | SSale | −444 | $20.26 | −$9.00K | −1.4%32.0K after | |
| Jan 31, 2023 (view filing) | Jan 27 | 4 days | Skolnick PhilChief Scientific Officer | SSale | −480 | $20.26 | −$9.72K | −2.2%21.5K after | |
| Jan 31, 2023 (view filing) | Jan 27 | 4 days | O'Toole David DChief Financial Officer | SSale | −541 | $20.26 | −$11.0K | −1.6%34.2K after | |
| Jan 9, 2023 (view filing) | Jan 9 | Same day | O'Toole David DChief Financial Officer | SSale | −415 | $20.20 | −$8.38K | −1.2%34.8K after | |
| Jan 9, 2023 (view filing) | Jan 9 | Same day | Ellison Mark Jason HeathChief Development Officer | SSale | −469 | $20.20 | −$9.47K | −2.4%19.4K after | |
| Jan 9, 2023 (view filing) | Jan 9 | Same day | Skolnick PhilChief Scientific Officer | SSale | −369 | $20.20 | −$7.45K | −1.6%22.0K after | |
| Jan 9, 2023 (view filing) | Jan 9 | Same day | Crystal RogerChief Executive Officer | SSale | −1.18K | $20.20 | −$23.9K | −1.5%76.7K after | |
| Jan 5, 2023 (view filing) | Jan 5 | Same day | Ellison Mark Jason HeathChief Development Officer | SSale | −1.81K | $20.20 | −$36.5K | −8.3%19.8K after |
Top 10 13F holders, Q4 2022
The largest institutional positions in Opiant Pharmaceuticals, Inc. at the end of Q4 2022; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Western Standard LLC | 424,080 | $8.60M | 7.57% | +424,080 | New |
| Apis Capital Advisors, LLC | 214,000 | $4.34M | 5.03% | +10,000+4.9% | Added |
| Morgan Stanley | 197,652 | $4.01M | 0.00% | +190,441+2,641.0% | Added |
| Vanguard Group Inc | 190,773 | $3.87M | 0.00% | +3,615+1.9% | Added |
| Renaissance Technologies LLC | 146,415 | $2.97M | 0.00% | −30,500−17.2% | Reduced |
| Wells Fargo & Company | 136,814 | $2.77M | 0.00% | −68,303−33.3% | Reduced |
| Dimensional Fund Advisors LP | 100,209 | $2.03M | 0.00% | −12,283−10.9% | Reduced |
| New York Life Investment Management LLC | 61,912 | $1.26M | 0.01% | +61,912 | New |
| CSS LLC | 61,349 | $1.24M | 0.08% | +61,349 | New |
| Parkman Healthcare Partners LLC | 59,943 | $1.22M | 0.32% | −16,587−21.7% | Reduced |